Shasank Chennupati

University of North Carolina at Chapel Hill

Economics, Econometrics and FinanceMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “Adverse events among chronic myelogenous leukemia patients treated with tyrosine kinase inhibitors: a real-world analysis of health plan enrollees”.

Adverse events among chronic myelogenous leukemia patients treated with tyrosine kinase inhibitors: a real-world analysis of health plan enrollees

Leukemia & lymphoma/Leukemia and lymphoma(2020)10.1080/10428194.2020.1855340

N/A

0.457DataRank · unranked

20 citations

David R. Doody, Jennifer J. Wilkes, Laura Becker, Shasank Chennupati, Pamela Morin +4 more

Health Care Cost Associated With Contemporary Chronic Myelogenous Leukemia Therapy Compared With That of Other Hematologic Malignancies

JCO Oncology Practice(2020)10.1200/op.20.00143

N/A

0DataRank · unranked

12 citations

Gary H. Lyman, David R. Doody, Shasank Chennupati, Laura Becker, Pamela Morin +4 more

Receipt of Screening Mammography by Insured Women Diagnosed With Breast Cancer and Impact on Outcomes

Journal of the National Comprehensive Cancer Network(2021)10.6004/jnccn.2020.7801

N/A

0DataRank · unranked

6 citations

Christoph I. Lee, Daniel S. Hippe, Shasank Chennupati, Catherine R. Fedorenko, Kathleen E. Malone +3 more